Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11857583 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL4346958 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL28070085 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL11512940 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL11865856 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL9244508 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL2428839 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL4334523 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL7208906 | 0.98 | TSHR (0.61) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL5098798 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101437849-B | insulin derivatives | NOVO NORDISK A/S (DK) | 2015-09-30 | — | — | CN | disclosed |
| EP-2386572-B1 | Insulin derivative | NOVO NORDISK AS (DK) | 2015-07-08 | — | — | EP | disclosed |
| US-8933021-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| EP-2015770-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2012-09-26 | — | — | EP | disclosed |
| EP-2386572-A1 | Insulin derivative | Novo Nordisk A/S (DK) | 2011-11-16 | — | — | EP | disclosed |
| US-8039101-B2 | Radio-opaque dental prosthetic member | Societe de Recherches Techniques Dentaires-R.T.D. (FR) | 2011-10-18 | — | — | US | disclosed |
| US-20090239785-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| CN-101437849-A | Insulin derivatives | NOVO NORDISK AS (DK) | 2009-05-20 | — | — | CN | disclosed |
| EP-2015770-A2 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007128817-A2 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
| US-7153844-B2 | Estrogen-linked platinum (II) complexes as anticancer agents | Berube, Gervais (CA) | 2006-12-26 | — | — | US | disclosed |
| US-20040006051-A1 | Estrogen-linked platinum (II) complexes as anticancer agents | GERVAIS BERUBE (CA) | 2004-01-08 | — | — | US | disclosed |
| EP-0684512-B1 | Photographic elements containing release compounds | EASTMAN KODAK CO (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5567577-A | COMPRISING A BLOCKING GROUP FROM WHICH THE PHOTOGRAPHICALLY ACTIVE MOIETY IS RELEASED, A BALLASTING GROUP AND AN AQUEOUS SOLUBILIZING GROUP | EASTMAN KODAK COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0684512-A1 | Photographic elements containing release compounds | EASTMAN KODAK COMPANY (US) | 1995-11-29 | — | — | EP | disclosed |
| US-4450149-A | REASCTING AN ORGANIC BORANE WITH A RADIOACTIVE HALOMONOCHLORIDE AND A MILD OXIDIZER; RADIOLOGY | RESEARCH CORPORATION (US) | 1984-05-22 | — | — | US | disclosed |
| US-3993773-A | Control of mites with esters of cyclopropane substituted carboxylic acids | ZOECON CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
| US-3969384-A | Esters of cyclopropane alkanoic acids | ZOECON CORPORATION (US) | 1976-07-13 | — | — | US | disclosed |
| US-3960907-A | MITICIDES | ZOECON CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239785-A1 | Insulin Derivative | IAPP, INSR, GPR119 | TSHR 1025/4885LMNA 2556/4885ALDH1A1 4280/4885 |
| US-20040006051-A1 | Estrogen-linked platinum (II) complexes as anticancer agents | ESR2, PGR, ESR1 | TSHR 655/4885LMNA 3285/4885ALDH1A1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.